The green tea polyphenol EGCG potentiates the antiproliferative activity of sunitinib in human cancer cells
详细信息 查看全文
- 作者：Yi Zhou ; Jie Tang ; Yang Du ; Jing Ding ; Ji-Yan Liu
- 刊名：Tumor Biology
- 出版年：2016
- 出版时间：July 2016
- 年：2016
- 卷：37
- 期：7
- 页码：8555-8566
- 全文大小：2,944 KB
- 刊物主题：Cancer Research;
- 出版者：Springer Netherlands
- ISSN：1423-0380
- 卷排序：37
文摘
Sunitinib is a promising drug for clinical applications; however, the efficacy is reduced by the feedback activation of many signaling cascades. In this study, we investigated the ability of (−)-epigallocatechin-3-gallate (EGCG) to synergize with sunitinib and inhibit insulin receptor substrate (IRS)/mitogen-activated protein kinase (MAPK) pathway activation. MCF-7, H460, and H1975 cell lines with PIK3CA mutations were treated with sunitinib or mock treated 0–24 h and then pulsed with 0–50 μM EGCG for another 12 h; cell proliferation and vascular endothelial growth factor (VEGF) secretion were then evaluated. To analyze angiogenesis and VEGF levels in vivo, MCF-7 and H460 xenograft tumors were established. Cell growth signaling cascades were assessed via western blotting in vitro, and tumors were subjected to immunohistochemical analyses to evaluate signaling cascades in vivo. EGCG enhanced the antiproliferation and VEGF secretion-reducing effects of sunitinib in the three tested cell lines. In vivo, EGCG administration at 4 h after sunitinib treatment resulted in greater tumor shrinkage and antiangiogenesis than with sunitinib alone. We further demonstrated that sunitinib exposure induces insulin receptor substrate-1 (IRS-1) upregulation and activation of MAPK signaling. More strikingly, EGCG treatment downregulated IRS-1 levels and suppressed mitogenic effects. In vivo, immunohistochemical analyses demonstrated marked suppression of the IRS/MAPK/p-S6K1 signaling cascade by EGCG, especially after sunitinib treatment. EGCG potentially synergizes with sunitinib due to its ability to suppress the IRS/MAPK signaling induced by sunitinib. We conclude that administration of EGCG after sunitinib treatment represents a promising strategy for the treatment of cancer.KeywordsCatechinPyrrolesFeedbackMAP kinase signaling systemInsulin receptor substrate proteins